BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M. Current Challenges and Controversies in Drug-Induced Liver Injury. Drug Saf 2012;35:1099-117. [DOI: 10.1007/bf03261997] [Cited by in Crossref: 44] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury. Liver Int. 2017;37:1582-1590. [PMID: 28386997 DOI: 10.1111/liv.13441] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 9.2] [Reference Citation Analysis]
2 Raschi E, Poluzzi E, Koci A, Caraceni P, De Ponti F. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601-612. [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.60] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Lewis JH. Causality assessment: which is best-expert opinion or RUCAM? Clinical Liver Dis. 2014;4:4-8. [PMID: 30992910 DOI: 10.1002/cld.365] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
4 Weng Z, Wang K, Li H, Shi Q. A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications. Oncotarget 2015;6:17031-8. [PMID: 26220713 DOI: 10.18632/oncotarget.4400] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
5 Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol 2014; 6(8): 601-612 [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.601] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
6 Longo DM, Yang Y, Watkins PB, Howell BA, Siler SQ. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury. CPT Pharmacometrics Syst Pharmacol 2016;5:31-9. [PMID: 26844013 DOI: 10.1002/psp4.12053] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
7 Raschi E, De Ponti F. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World J Hepatol 2015; 7(13): 1761-1771 [PMID: 26167249 DOI: 10.4254/wjh.v7.i13.1761] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
8 Sirenko O, Hesley J, Rusyn I, Cromwell EF. High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells. Assay Drug Dev Technol 2014;12:43-54. [PMID: 24229356 DOI: 10.1089/adt.2013.520] [Cited by in Crossref: 91] [Cited by in F6Publishing: 77] [Article Influence: 10.1] [Reference Citation Analysis]
9 Lai SW, Lin CL, Liao KF. Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan. Front Pharmacol 2017;8:767. [PMID: 29123484 DOI: 10.3389/fphar.2017.00767] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
10 Rose KA, Holman NS, Green AM, Andersen ME, LeCluyse EL. Co-culture of Hepatocytes and Kupffer Cells as an In Vitro Model of Inflammation and Drug-Induced Hepatotoxicity. J Pharm Sci 2016;105:950-64. [PMID: 26869439 DOI: 10.1016/S0022-3549(15)00192-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
11 Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J 2018;39:2526-39. [PMID: 29718253 DOI: 10.1093/eurheartj/ehy182] [Cited by in Crossref: 137] [Cited by in F6Publishing: 97] [Article Influence: 45.7] [Reference Citation Analysis]
12 Amacher DE, Schomaker SJ, Aubrecht J. Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics. Mol Diagn Ther 2013;17:343-54. [PMID: 23868512 DOI: 10.1007/s40291-013-0049-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
13 Lahiri DK, Maloney B, Long JM, Greig NH. Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement 2014;10:S411-9. [PMID: 24530026 DOI: 10.1016/j.jalz.2013.11.004] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
14 Schomaker S, Potter D, Warner R, Larkindale J, King N, Porter AC, Owens J, Tomlinson L, Sauer JM, Johnson K, Aubrecht J. Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments. PLoS One 2020;15:e0229753. [PMID: 32407333 DOI: 10.1371/journal.pone.0229753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]